Completed PHASE3 INTERVENTIONAL NCT00095134

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Sponsor: Janssen, LP

Conditions Major Depressive Disorder

Interventions risperidone

Updated 6 times since 2017 Last updated: Dec 5, 2011 Started: Oct 31, 2004 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Major Depressive Disorder, this trial is completed. The trial is conducted by Janssen, LP and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen, LP
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alliance, United States , Arlington Heights, United States , Avon, United States , Beaumont, United States , Birmingham, United States , Burbank, United States , Cadillac, United States , Canal Fulton, United States , Cincinnati, United States and 53 more locations